174 related articles for article (PubMed ID: 38112541)
21. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
[No Abstract] [Full Text] [Related]
22. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
[TBL] [Abstract][Full Text] [Related]
23. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study.
Ludwig DR; Romberg EK; Fraum TJ; Rohe E; Fowler KJ; Khanna G
Pediatr Radiol; 2019 May; 49(6):746-758. PubMed ID: 31069473
[TBL] [Abstract][Full Text] [Related]
25. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
[TBL] [Abstract][Full Text] [Related]
26. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.
Granata V; Grassi R; Fusco R; Setola SV; Belli A; Piccirillo M; Pradella S; Giordano M; Cappabianca S; Brunese L; Grassi R; Petrillo A; Izzo F
Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33808466
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
29. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
30. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
[TBL] [Abstract][Full Text] [Related]
31. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
32. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
34. Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024.
Lyshchik A; Fetzer DT; Kono Y; Wilson SR; Dietrich CF; Clevert DA; Meloni MF; Jang HJ; Kim TK; Lee JM; Minami Y; Kudo M; Piscaglia F
Radiology; 2024 May; 311(2):e232369. PubMed ID: 38805727
[TBL] [Abstract][Full Text] [Related]
35. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
36. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
[TBL] [Abstract][Full Text] [Related]
37. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
38. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
39. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study.
Piñero F; Thompson MA; Diaz Telli F; Trentacoste J; Padín C; Mendizabal M; Colaci C; Gonzalez Campaña A; Pages J; Montal S; Barreiro M; Fauda M; Podestá G; Perotti JP; Silva M
Ann Hepatol; 2020; 19(6):662-667. PubMed ID: 32683095
[TBL] [Abstract][Full Text] [Related]
40. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]